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Transforming growth factor-beta (TGF-β) superfamily signaling has been implicated in many developmental processes, including pancreatic
development. Previous studies are conflicting with regard to an exact role for TGF-β signaling in various aspects of pancreatic organogenesis.
Here we have investigated the role of TGF-β isoform signaling in embryonic pancreas differentiation and lineage selection. The TGF-β isoform
receptors (RI, RII and ALK1) were localized mainly to both the pancreatic epithelium and mesenchyme at early stages of development, but then
with increasing age localized to the pancreatic islets and ducts. To determine the specific role of TGF-β isoforms, we functionally inactivated
TGF-β signaling at different points in the signaling cascade. Disruption of TGF-β signaling at the receptor level using mice overexpressing the
dominant-negative TGF-β type II receptor showed an increase in endocrine precursors and proliferating endocrine cells, with an abnormal
accumulation of endocrine cells around the developing ducts of mid–late stage embryonic pancreas. This pattern suggested that TGF-β isoform
signaling may suppress the origination of secondary transition endocrine cells from the ducts. Secondly, TGF-β isoform ligand inhibition with
neutralizing antibody in pancreatic organ culture also led to an increase in the number of endocrine-positive cells. Thirdly, hybrid mix-and-match
in vitro recombinations of transgenic pancreatic mesenchyme and wild-type epithelium also led to increased endocrine cell differentiation, but
with different patterns depending on the directionality of the epithelial–mesenchymal signaling. Together these results suggest that TGF-β
signaling is important for restraining the growth and differentiation of pancreatic epithelial cells, particularly away from the endocrine lineage.
Inhibition of TGF-β signaling in the embryonic period may thus allow pancreatic epithelial cells to progress towards the endocrine lineage
unchecked, particularly as part of the secondary transition of pancreatic endocrine cell development. TGF-β RII in the ducts and islets may
normally serve to downregulate the production of beta cells from embryonic ducts.
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The early stages of pancreatic development entail a primary
lineage selection by the pancreatic epithelium between endo-
crine and exocrine lineages (Gittes et al., 1996; Miralles et al.,
1998b). This selection appears to be determined by stimuli from
the associated pancreatic mesenchyme (Golosow and Grob-
stein, 1962; Rutter et al., 1978). Later in gestation, starting at
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very different pathway appears to give rise to new endocrine
cells, presumably from ducts (Pictet and Rutter, 1972). Specific
control points for this transition are not well delineated. The
embryonic pancreatic milieu, including the pancreatic mesench-
yme, consists of numerous soluble, membrane-bound, extra-
cellular and matrix-bound factors that may control pancreatic
development and differentiation. Among such factors, many of
the transforming growth factor-beta (TGF-β) superfamily
members have been suggested to play an important role
(Bottinger et al., 1997; Kim et al., 2000; Lee et al., 1995;
Miralles et al., 1998a; Rawdon and Andrew, 1998; Ritvos et al.,
1995; Sanvito et al., 1994; Yamaoka et al., 1998).
The TGF-β superfamily consists of three main subfamilies:
TGF-β isoforms (numbered 1–3 in mammals), BMPs and
activins. All are multifunctional proteins that regulate cell
proliferation, lineage determination, differentiation and extra-
cellular matrix synthesis. Canonical TGF-β superfamily
signaling entails binding a type I and type II transmembrane
serine/threonine kinase receptor. Upon binding ligands, type II
receptors recruit and phosphorylate type I receptors, which in
turn activate downstream smads, that mediate TGF-β-regulated
gene expression (Massague, 1998; Shi and Massague, 2003).
Several studies have suggested a role for the TGF-β isoform
subfamily in the regulation of pancreatic organogenesis, but
with conflicting results. A clear and specific role for TGF-β
isoform signaling in pancreatic development remains elusive.
Much of the previous work focused on late gestational effects or
in adult transgenics (Lee et al., 1995; Miralles et al., 1998a;
Sanvito et al., 1994, 1995), adult islets (Shalev et al., 2002) or
engineering of embryonic stem cells (Skoudy et al., 2004).
However, Sanvito et al. (1994, 1995) reported a potential pro-
endocrine effect of the TGF-β1 present in Matrigel on early
(E11.5) embryonic mouse pancreas development. Here a
prolonged in vitro culture with a progressive loss of acinar
tissue suggested that there may have been significant acinar
autolysis with relative endocrine sparing, which could have
been perceived as a pro-endocrine effect. In addition, these early
studies were not able to delve into the complexity of potential
TGF-β isoform signaling pathways due to the relative lack of
knowledge in the field at that time. Thus, the role of TGF-β
isoform signaling in endocrine versus exocrine lineage selec-
tion, as well as in the amplification of those lineages, remains
unclear. We previously demonstrated expression of TGF-β1,
-β2 and -β3 starting from the early embryonic pancreatic
epithelium through to late gestation endocrine and exocrine
pancreas (Crisera et al., 1999). In addition, manipulations of
TGF-β isoform signaling have been shown to affect adult
pancreatic differentiation (Bottinger et al., 1997).
In this study, we have used several approaches to investigate
the specific role of TGF-β isoform signaling in early pancreatic
organogenesis. First, we studied the endogenous expression of
TGF-β isoform receptors during pancreas development and
correlated expression with lineage selection. Second, we studied
the effect of inhibiting TGF-β isoform signaling in the
developing pancreas using a transgenic mouse expressing a
dominant-negative TGF-β type II receptor (DNTβRII). Theadult phenotype of these transgenic mice has been previously
reported (Bottinger et al., 1997). We also inhibited TGF-β
signaling in vitro, using either ligand inhibition with TGF-β
isoform pan-neutralizing antibody or receptor inhibition with
the recombination of epithelia or mesenchyme from early
DNTβRII transgenic pancreatic rudiments with wild-type
counterparts.
Our results show that the endogenous TGF-beta type II
receptor (TGF-β RII) and type I receptor (TGF-β RI or ALK5)
are localized differentially to the epithelium and mesenchyme at
early stages and then localize to pro-endocrine/endocrine
structures and ducts at later stages of pancreatic development.
Blocking TGF-β signaling in the embryonic pancreas, either
with the dominant-negative receptor transgenic mice or with
TGF-β-specific pan-neutralizing antibody, led to an increased
number of endocrine cells. Interestingly, when TGF-β RII
function was blocked in only the mesenchyme, by combining
transgenic pancreatic mesenchyme with age-matched wild-type
pancreatic epithelia, the greatest increase in the number of
endocrine cells was seen. These data indicate that absence of
TGF-β isoform signaling in the early embryonic period, both in
pancreatic epithelium and in mesenchyme, may direct pancrea-
tic epithelial cells towards the endocrine lineage, leading to
growth and differentiation of endocrine cells. Importantly,
signaling through endogenous TGF-β receptors in the ducts and
islets may normally serve to downregulate proliferation and
differentiation of new endocrine cells, via either neogenesis
from ducts or proliferation of existing insulin-positive cells, in
what is considered the secondary transition of pancreatic
endocrine development.Materials and methods
Transgenic animals and genotyping
All the animal experiments were performed in accordance with guidelines
established by the animal care facility of University of Pittsburgh and University
of Missouri Kansas City. Transgenic mice expressing a dominant-negative TGF-
βRII (DNTβRII), under the control of constitutive metallothionine (MT-1)
promoter, were generous gifts from Dr. Lalage Wakefield and Erwin Bottinger.
These mice were bred and embryos were harvested on gestational day E11.5,
E12.5, E14.5, E16.5 and E18.5. Non-pancreatic tissues from the embryos were
used for genotyping with the Extract-N-Amp PCR mix (Sigma, St. Louis, MO)
kit and PCR probe that is specific for the transgene. Pancreata were isolated by
microdissection from the transgenic embryos as well as from the CD1 littermate
controls. When indicated, the activity of the MT-1 promoter was enhanced by
maintaining the pregnant animals on drinking water containing 25 mM ZnSO4.
Organ culture
Neutralizing antibody experiment: Dorsal pancreatic rudiments of E11.5
CD1 mouse embryos were grown in hanging drop organ culture containing
TGF-β isoform pan-neutralizing antibody (Upstate biotechnology). Non-
immune rabbit serum was used as a control. A drop, consisting of 50 μl of
control media or media containing neutralizing antibody 80 μg/ml, was placed
on a 35-mm Petri dish. Pancreas rudiment was placed inside the drop and
inverted so that the drop hangs. The bottom of the Petri dish was filled partially
with media to keep the environment moist. The drop was replaced every day and
the cultures were maintained for 6 days at 37 °C and 5% CO2.
Mix-and-match experiment: Time-dated CD1 and DNTβRII mice were
sacrificed at E11.5. Pancreatic epithelium and mesenchyme were separated by
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drop cultures were carried out between wild-type CD1 and transgenic DNTβRII
pancreatic epithelium and mesenchyme. 10−5 M zinc chloride was added to the
media to activate the MT-1 promoter. The cultures were maintained for 6 days.
Histology and immunohistochemistry
Harvested tissues were fixed in 4% paraformaldehyde, cryoprotected by
incubating in 30% sucrose overnight, embedded in Tissue Tek OCT compound
and frozen in Liquid N2. Sections (6–8 μm) were cut by cryostat, and
hematoxylin and eosin (H&E) staining was done by standard protocol. For
immunohistology, optimal dilutions and controls were used for each antibody
used. DNTβRII was detected after antigen retrieval with sodium citrate (10 mM,
pH 3.0) by polyclonal rabbit anti-human TβRII 1:100 (residues 1–28, Upstate
biotechnology, VA). Insulin guinea pig anti-swine 1:400 (Dako, Carpinteria,
CA), glucagon mouse monoclonal 1:500 (Sigma, St. Louis, MO), amylase rabbit
anti-human 1:400 (Sigma, St. Louis, MO), endogenous TGF-β RII rabbit
polyclonal anti-human 1:75 (Santa Cruz biotech, CA), TGF-β RI (ALK5) rabbit
polyclonal anti-human 1:75 (Santa Cruz biotech, CA), ALK1 rabbit polyclonal
anti-human 1:40 (Santa Cruz Biotech, CA), PDX-1 rabbit polyclonal 1:1400
(generous gift from Prof. Chris Wright, Vanderbilt University Medical School,
Nashville, TN), CD-31 rat monoclonal anti-mouse 1:50 (BD Pharmingen, CA),
neuroD1 rabbit polyclonal 1:100 (Santa Cruz Biotech, CA), cleaved caspase-3
rabbit monoclonal cleaved 1:100 (Cell signaling Tech, MA), neurogenin-3 mouse
monoclonal 1:3000 (Beta Cell Biology Consortium, TN) and DBA FITC
conjugated 1:100 (Vector Laboratories, CA). Primary antibodies were incubated
for 1 h at room temperature or at 4 °C overnight. BiotinylatedVectastainABCkit or
AMCA/CY3/FITC fluorescent-conjugated donkey secondary antibodieswere used
for 1 h at room temperature. Immunoperoxidase was detected by DAB kit (Dako,
Carpintaria, CA) or AEC (Sigma, St. Louis,MO) and fluorescently labeled samples
were imaged using a fluorescent microscope.
Bromo-deoxyuridine (BrdU) incorporation
Pregnant mice were injected with BrdU (Sigma, St. Louis, MO) 200 mg/kg
intraperitoneally 2 h prior to harvesting the embryos. The pancreata were fixed,
sectioned and slides treated with 2 N HCl for 15 min, then 0.5% Pepsin in 0.1 N
HCl for 15 min at room temperature. To determine the proportion of
proliferating endocrine cells (sum of insulin- and glucagon-positive cells), we
used high power images (×400) taken from sections that were stained with
insulin or glucagon and BrdU (Dako, Carpintaria, CA) and DAPI nuclear
counterstaining. Cells positive for BrdU and endocrine cells were counted in at
least six sections obtained from four independent mice.
Quantitative analysis
Serial 8-μm sections were cut and collected in glass slides. One out of twelve
(for in vivo experiments) or seven (for in vitro experiments) consecutive sections
were analyzed by immunohistochemistry and microscopic images were captured
using 100× and 200× magnification. The results of each experiment were
obtained by quantifying the positive staining area for the given antigen in at least
4 pancreatic rudiments. Data are presented as percentage of positive area per
gross total area of the pancreas using Image-Pro Plus (Media Cybernetics, Silver
Spring, MD). Statistical analysis was performed using Student t-test and P value
<0.05 was considered as statistically significant.
RNA extraction and semi-quantitative reverse transcriptase-PCR
Total RNAwas isolated from whole pancreas of E11.5, E12.5, E14.5, E16.5
and E18.5 transgenic or wild-type mice using Qiagen RNeasyMini kit, followed
by Promega RQ1 DNase I treatment. First-strand cDNA was synthesized by
using sensiscript Reverse Transcriptase kit (Promega). Real-time semi-
quantitative PCR reactions were carried out with SyberGreen PCR Master
Mix in iCycler iQ apparatus (Bio-Rad, Hercules, CA). A mouse β-tubulin
primer set was used to normalize the amount of total cDNA for each gene
expression. Various concentrations of wild-type or transgenic cDNA (107,
106,105, 104, 103, 102 molecules/μl) were used for the calibration of standardcurve for each primer set. In addition, the PCR products were separated and
visualized on the agarose gel for confirmation. At least five different samples
were analyzed at each sequential age to quantify the target gene. Primers were
designed by primer3_www.cgi v 0.2 software. Oligos sequences used are listed
as forward then reverse, 5′ to 3′: β-Tubulin 5′CCTTTTGGCCAGATCTT-
CAG3′ and 5′AACCAACTCAGCTCCCTCTG3′ amplify a product of 102 bp,
Transgene (DNTβRII) 5′GCATCAGAAGAGGCCATCAA3′ and 5′ACT-
CACCCTGAAGTTCTCAG3′ amplify a product of 224 bp, TGF-β RII 5′
CAATGCTGTGGGAGAAGTGA3′ and 5′CTCACACACGATCTGGATGC3′
amplify a product of 163 bp, TGF-β RI (ALK5) 5′ATTGCTGGTC-
CAGTCTGCTT3′ and 5′CCTGATCCAGACCCTGATGT3′ amplify a product
of 188 bp, ALK1 5 ′TGACCTCAAGAGTCGCAATG3 ′ and 5 ′
GTTGTTGCCGATATCCAGGT3′ amplify a product of 115 bp, TGF-β1 5′
TGGAGCAACATGTGGAACTC3′ and 5′CGTCAAAAGACAGC-
CACTCA3′ amplify a product of 108 bp, TGF-β2 5′TGGCTTCACCACAAA-
GACAG3′ and 5′CCTCGAGCTCCTTCGCTTTTA3′ amplify a product of
115 bp, TGF-β3 5′GATGAGCACATAGCCAAGCA3′and 5′ATTGGGCT-
GAAAGGTGTGAC3′ amplify a product of 177 bp, neuroD1 5′CTCT-
GGAGCCCTTCTTTGAA3′ and 5′TGCAGGGTAGTGCATGGTAA3′
amplify a product of 161 bp, neurogenin-3 5′TTCGCCCACAACTA-
CATCTG3′ and 5′CAGGGAATTCCTCCAATGAG3′ amplify a product of
199 bp.Results
Basic phenotype of DNTβRII transgenic mouse embryonic
pancreas
To examine the embryonic phenotype of the dominant-
negative type II TGF-β receptor (DNTβRII) transgenic mice,
we first studied histology and immunohistochemistry for
markers of pancreatic differentiation in sequential ages of
embryonic pancreas (Fig. 1 and Supplementary Fig. 1). At
E11.5 and E12.5, there were no appreciable differences grossly,
histologically nor immunohistochemically between the
DNTβRII transgenic embryos and wild-type littermates,
regardless of whether transgene expression was further
enhanced with ZnSO4 (Supplementary Fig. 1). However, by
E14.5, the early phase of the secondary transition, transgenic
pancreata, began to show abnormal expansion of the endocrine
and potentially the pro-endocrine components (see below) of
the epithelium, with an increase in both insulin- and glucagon-
positive cells (Figs. 1Ab, c). At E16.5, the phenotype of the
DNTβRII embryonic pancreas diverged markedly from wild-
type littermates. The gestational timing of this phenotypic
divergence coincides with a period of profound exocrine and
endocrine differentiation and expansion in normal embryonic
pancreas. The transgenic pancreas had prominent expansion of
the cord region (central region that typically harbors the
endocrine cells), with periductal accumulation of cells. The
majority of the periductal cells were endocrine, expressing
insulin and glucagon (Figs 1Ae, f and 2Ab, Bb). Many
periductal cells stained for pro-endocrine markers neurogenin-3
and neuroD1 (see below and Fig. 4). Quantitative analysis
showed a significant increase in insulin-positive cells at this
age, with some further augmentation seen in zinc-treated
animals (Fig. 1C), representing a form of dose–response of
these cells to TGF-β isoform inhibition. The insulin-positive
cells appear to be mature beta cells as evidenced by positive
staining for PDX-1 (Fig. 2Ab). At E18.5, continued cord region
Fig. 1. Phenotype of DNTβRII transgenic mouse embryonic pancreas: (A) Embryonic pancreata at various gestational time points were analyzed by immunostaining
for markers of pancreatic differentiation. Amylase (red), insulin (blue) and glucagon (green) in wild-type CD1 (a, d, g), transgenic DNTβRII (b, e, h) and transgene-
induced DNTβRII+Zn (c, f, i). At E14.5 (a–c), transgenic pancreas showed increased expansion of the “cord region” (defined as the more central region of the
pancreas where typically the endocrine cells are found). At E16.5 (d–f), the transgenic phenotype diverged most markedly from controls. The transgenic pancreas had
prominent expansion of the cord region with an increase in endocrine cells, most notably in Zn-treated embryos. At E18.5 (g–i), continued cord region expansion was
seen. (B) Transgene-induced DNTβRII+Zn pancreata at E16.5 (b) and E18.5 (d) showed increased and abnormally dilated blood vessels, as shown by CD31 (red)
staining. (C) Quantitative analysis of E16.5 pancreas showed a significant increase in the amount of insulin-positive area and in the amount of CD31-positive
endothelium in transgenic pancreas compared to wild-type. *P value <0.05 and scale bar 60 μm.
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(Supplementary Fig. 4) described previously for the adult
pancreas (Bottinger et al., 1997). In spite of their abnormal
appearance, the atypical acini of the transgenic pancreas did
express amylase (Figs. 1Ah, i and 2Bd). E16.5 and E18.5
transgenic pancreata also showed a significant increase in the
number of blood vessels, as shown by an increase in staining for
the vascular endothelial marker CD-31 (Figs. 1Bb, d). Some of
the transgenic pancreata exhibited abnormally dilated blood
vessels with focal areas of congestion. However, the endothelial
lining of these abnormal blood vessels appears to be intact,
suggesting that the clusters of red blood cells may not be from
hemorrhage but rather from stagnant blood in malformed vessels
(Supplementary Fig. 1). This abnormal vascular phenotype is
reminiscent of a diffuse vasculopathic phenotype seen in several
null mutant mouse strains, including TGF-β1 (Dickson et al.,
1995), TGF-βRII (Oshima et al., 1996), endoglin (Bourdeau et
al., 2001) and ALK1 null mutants (Larsson et al., 2001; Oh et al.,
2000).Proliferation of endocrine and pro-endocrine cells in
embryonic DNTβRII transgenic pancreas
To investigate the mechanism of increase in endocrine cells
in mid-gestation embryonic transgenic pancreas, we examined
the presence of pro-endocrine cells and the proliferative status
of the endocrine cells at different embryonic time points.
Proliferating cells were assessed by bromo-deoxyuridine
incorporation, and then immunostaining with insulin or glucagon
and anti-BrdU antibodies. In general, the control CD1 embryonic
pancreas had few proliferating endocrine cells (Sander et al.,
2000) (Figs. 3Aa, c and 6H). However, the proliferative status of
the endocrine cells in transgene-induced pancreas was signifi-
cantly increased at E16.5 (Figs. 3Ab, B,Cb, D and Supplementary
Fig. 2). Proliferating ductal structures, as evidenced by double
staining for DBA and BrdU, were also more apparent in the
transgenic pancreas at this age (Supplementary Fig. 2), consistent
with an amplified secondary transition. But by E18.5, the
proliferative nature of the insulin- or glucagon-positive cells in
Fig. 2. Transgenic phenotype: expansion of the cord region with periductal accumulation of endocrine cells. Immunohistochemical analysis of embryonic pancreas in
panel Awith duct marker DBA (green), insulin (blue) and PDX-1 (red) and in panel B with insulin (red), amylase (blue) and DBA (green) of wild-type CD1 (a, c) or
transgene-induced DNTβRII+Zn (b, d) at E16.5 (a, b) and E18.5 (c, d) showed prominent expansion of cord region with increased accumulation of endocrine cells in
periductal region. Scale bar 60 μm.
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endocrine markers neurogenin-3 and neuroD1 were also more
highly expressed in transgene-induced pancreas at E14.5 and
E16.5 (Figs. 4Ab, d and Cb, d). At E16.5, there were abundant
neurogenin-3-positive cells in and around the DBA-positive ducts
(green) of transgene-induced pancreas compared to wild-type
controls. Quantitative RT-PCR analysis of the pro-endocrine
markers in transgene-induced pancreas showed statistically
significant increase in mRNA expression of neurogenin-3 at
E14.5 and E16.5 (Fig. 4B). Similarly, mRNA expression of
neuroD1 was significantly upregulated at E16.5 (Fig. 4D). Since
neuroD1 is a post-mitotic marker, this higher expression may
portend the stoppage of proliferation by E18.5. In addition to the
decrease in enhanced proliferation of the endocrine cells at this
stage, there was also a concomitant increase in caspase-3-positive
apoptotic endocrine cells in the transgene-induced pancreas
(Supplementary Fig. 3).
Ontogeny of TGF-β receptor isoforms in embryonic pancreas
In order to determine the role of endogenous TGF-βRII and
potential type I receptors mediating TGF-β isoform signaling in
pancreatic organogenesis, we first performed ontogeny studies
of receptors important for TGF-β isoform signaling (Fig. 5).
The endogenous type II (TGF-β RII) receptor was expressed
strongly in the epithelium at E11.5 and E12.5, in the cord region
(pro-endocrine central region around ducts) at E14.5 and in the
ducts and blood vessels at E16.5 and E18.5. The type II receptor
only expressed weakly, however, in the mesenchyme, at E11.5
and E12.5 (Figs. 5A, D). Similarly, receptor type I (TGF-β RI orALK5) was expressed strongly in the epithelium at E11.5 and
E12.5 and in the developing cord region at E14.5. At E16.5, it
was expressed not only in the ducts and cord region but also in
the developing blood vessels. At E18.5, it was predominantly
expressed in ducts. The mesenchyme appeared to have weak
expression for TGF-β RI at E11.5 and E12.5 (Figs. 5B, E).
Taken together, because of the parallel spatiotemporal expres-
sion pattern of receptor II and receptor I, these results support a
role for TGF-β isoforms binding to the heterodimeric receptor
TGF-β RI with RII. This ligand binding may occur in both the
mesenchyme and epithelium early in gestation, and later only in
the epithelium, especially in the cord region and ducts. Based on
the findings in the mutant mice discussed above, this binding
may act to prevent or regulate expansion and differentiation of
precursor cells in the cord region to form new endocrine cells.
We also examined the ALK1 receptor (Figs. 5C, F, I, L, O),
which can also bind TGF-β isoforms, but unlike TGF-β RI
activates the BMP-specific SMADs (Smad 1, 5 and 8) and can
compete with the TGF-β RI for TGF-β isoform binding. We
found ALK1 to be expressed at low levels in the epithelium at
E11.5 (Fig. 5C) and in the epithelium and weakly in the
mesenchyme (possibly in the vasculogenic mesenchyme) at
E12.5. At E14.5, it was expressed weakly in the cord region,
similar to TGF-β RI, thus suggesting possible competition
between ALK1 and ALK5 for binding TGF-β isoforms. Lastly,
at E16.5 and E18.5, ALK1 was mainly expressed in the blood
vessels and, to a lesser extent, in the cord region. The
overlapping expression of RII and ALK1 in the vasculature at
E16.5 and E18.5 suggests a role for a heterodimer of those two
receptors in regulating blood vessel development.
Fig. 3. Increased proliferation of endocrine cells in the embryonic pancreas of transgenic mice: proliferating endocrine cells in the embryonic pancreas were examined
through BrdU incorporation and then staining for BrdU (red/green) and (A) insulin (green) or (C) glucagon (red). At E16.5 and E18.5, the control wild-type CD1
endocrine cells showed low proliferation with few BrdU and insulin/glucagon-positive cells (a, c). However, at E16.5 the proliferative status of the insulin or glucagon
cells in transgene-induced pancreas was significantly increased (arrowhead b). Quantitative analysis of proliferating endocrine cells in transgene-induced pancreas
showed a significant increase in proliferation of insulin-positive (B) and glucagon-positive cells (D) at E16.5. However, the level of proliferation became similar to
wild-type by E18.5. *P value <0.05 and scale bar 60 μm.
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DNTβRII pancreas
In order to inhibit endogenous TGF-β isoform signaling, the
transgenic dominant-negative receptor must be expressed at a
high level and in the same cells that express the endogenous
receptor. Thus, in order to better understand the phenotype in
the embryonic transgenic mice, we examined the embryonic
pancreas of DNTβRII mice for transgene expression by
immunohistochemistry using anti-human TGF-β RII (1–28,
Upstate biotechnology) antibody that only recognizes the
human transgenic receptor, not the endogenous receptor. The
expression level was compared between zinc-treated and
-untreated embryonic pancreas (Fig. 6, non-transgenic tissues
stained negative, data not shown).
At E11.5 the transgene was absent unless induced by zinc.
Addition of zinc augmented some localized expression in the
epithelium (Fig. 6B). At E12.5, transgene expression began to
appear in the epithelium without zinc. However, with the
addition of zinc strong expression was seen in the epithelial cord
(or pro-endocrine) region and very clearly in the mesenchyme(Fig. 6D). This early expression of the transgene could be
inhibiting TGF-β isoform signaling, leading to the subsequent
expansion of the cord region seen later in the transgenic
embryos. At E14.5, there was only cord region/pro-endocrine
expression of the transgene, either with or without zinc, but the
expression again appeared much stronger with zinc. In addition,
some expression in acinar cells was seen only in the zinc-treated
group. This early acinar expression may be a harbinger of the
acinar atypia seen late in gestation and postnatally in these
animals. The expression pattern at E14.5 also supports the
enhancement of endocrine differentiation that we see by E16.5,
especially in the presence of zinc (Figs. 1Af and C). At E16.5,
the transgene was expressed weakly in the cord region even
with zinc and became quite strong in the acinar cells with or
without zinc (Figs. 6G, H). This change in expression may
explain both the decreasing endocrine phenotype seen at E18.5,
as well as the early development of acinar atypia at E18.5.
These data suggest that signaling through TGF-β RII is
necessary for both endocrine and exocrine maturation at
different phases of development. At E18.5, essentially all of
the transgene expression was in the acini, and the level of
Fig. 4. Increased endocrine precursors in the embryonic pancreas of transgenic mice: immunohistochemical analysis showed increased expression of endocrine
precursor (A) neurogenin-3-positive (red) and (C) neuroD1-positive (red) cells in the transgene-induced pancreas at E14.5 (a, b) and E16.5 (c, d). At E16.5, there were
abundant neurogenin-3-positive cells in and around the DBA-positive ducts (green) of transgene-induced pancreas. Quantitative RT-PCR analysis of transgene-
induced pancreas showed significant upregulation in panel B neurogenin-3 and (D) neuroD1 mRNA expression. *P value <0.05 and scale bar 60 μm.
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and -untreated groups, which may explain the lack of an adult
endocrine phenotype in these mice (Figs. 6I, J).
Quantification of the endogenous and transgenic receptor
mRNA
A significantly higher expression level of the transgene than
of the endogenous receptor is necessary for effective inhibition.
Therefore, quantification of the TGF-β receptors’ mRNA was
performed at various gestational time points by semi-quantita-
tive RT-PCR (Figs. 7A–C). The endogenous TGF-β RII mRNA
level gradually increased over gestation, consistent with a
greater role late in gestation. On the other hand, low expressions
at early stages imply that its function would be more easily
overridden by the dominant-negative transgene, thus making
the younger embryonic pancreas potentially more likely to
display a phenotype in the transgenic animals (Fig. 7A). TGF-β
RI mRNA (ALK5) showed the highest level of expression at
E16.5 and then a sharp decline at E18.5, suggesting an
important role early at E14.5 and E16.5 (Fig. 7B). This
temporal pattern implies that the strong phenotype seen in the
TGF-β RII transgenic mice at mid-gestational time points maybe due to inhibition of TGF-β RII binding to ALK5. The drop in
ALK5 mRNA levels at E18.5 suggests that other ALKs,
particularly ALK1, may instead dimerize with TGF-β RII to
mediate other actions, such as blood vessel development. The
ALK1 mRNA level rises suddenly late in gestation, consistent
with a possible role in blood vessel formation and/or growth
(Fig. 7C), also supported by the apparent vascular phenotype
seen at E16.5 and E18.5.
PCR quantification of the transgenic dominant-negative
receptor showed significant upregulation of expression in zinc-
treated pancreas at E11.5, E12.5 and E14.5 compared to
untreated embryos (Fig. 7D and inset). This pattern may also
help to explain the stronger endocrine phenotype in zinc-treated
pancreas at E16.5 compared to those without zinc treatment.
However, the baseline expression of the transgene at E16.5 and
E18.5 becomes very high, even in the absence of zinc. This
baseline increase may be due to expression of the transgene in
the acinar tissue alone at later stages of development, as was
seen with the immunohistochemistry (Fig. 6). Addition of zinc
at these later ages did not seem to affect the expression level of
the transgene. This change in expression may contribute to the
primarily acinar phenotype seen in postnatal and adult
transgenic mice.
Fig. 5. Ontogeny of endogenous TGF-β isoform receptors: expression of TGF-βRII (A, D, G, J, M) and expression of the two potential type I receptor binding
partners of TGF-βRII, i.e., TGF-βRI/ALK5 (B, E, H, K, N) and ALK1 (C, F, I, L, O) was examined in wild-type embryonic pancreases at various time points of
gestation. The expression of TGF-βRII in epithelium (arrows) was stronger and more localized compared to mesenchyme (arrowhead) at E11.5 and E12.5. At E14.5
and E16.5, TGF-βRII appeared to be mainly expressed in the pro-endocrine cord region (arrowheads) and in the ducts (arrows), and then at E18.5 predominantly in
ducts (arrows) and blood vessels (arrowheads). The expression pattern of TGF-βRI/ALK5 paralleled TGF-βRII. ALK1 expression showed a different pattern, with
low levels in the epithelium (arrow) at E11.5 (C), low levels in the epithelium (arrow) and very low levels in mesenchyme (arrowhead) at both E12.5 (F) and E14.5
(G). At E16.5 and E18.5, ALK1 was mainly expressed in blood vessels (L, O, arrowheads). The overlapping expression of RII and ALK1 in vasculature at this
stage may suggest a role for the TGF-β RII/ALK1 dimer in regulating blood vessel development. Scale bar 60 μm.
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pancreas
To compare the level of TGF-β ligands between wild-type
and transgenic mice, we used semi-quantitative mRNA
expression analysis (Figs. 7E–G). The expression levels for
the three ligands were fairly similar between wild-type and
transgenic mice through E16.5. However, the level of expres-
sion then differed selectively at E18.5. The level of TGF-β1 and
TGF-β3 significantly increased in transgenic pancreas treated
with zinc (Figs. 7E, G and P value <0.05). On the other hand,
the level of TGF-β2 was lower in transgenic pancreas when
compared with wild-type (Fig. 7F). These results are consistentwith the previous study in adult DNTβRII transgenic pancreas
(Bottinger et al., 1997). These changes in the level of TGF-β
ligands, together with the changes in expression pattern of the
transgene in transgenic pancreas at late gestation, may help to
explain the lack of an endocrine phenotype late in gestation and
postnatally.
In vitro mix-and-match experiments
In order to study the role of TGF-β RII signaling specifically
in either the pancreatic mesenchyme or in the epithelium, we
performed a series of in vitro recombination experiments
between transgenic (TGF-β RII dominant negative) and wild-
Fig. 6. Ontogeny of the transgene in embryonic DNTβRII pancreas by immunohistochemistry: the expression was compared between zinc-treated and -untreated
embryonic pancreas. At E11.5, the transgene was absent unless induced by zinc. Addition of zinc at E11.5 augmented expression in the epithelium (arrows) and weakly
in the mesenchyme (arrowheads). At E12.5, transgene expression began to appear in the epithelium even without zinc (arrows). However, with zinc, strong expression
was seen not only in the epithelium at E12.5 (arrows) but also very clearly in the mesenchyme (arrowheads). At E14.5, only the cord or pro-endocrine region
(arrowheads) expressed the transgene, either with or without zinc, but expression appeared much stronger with zinc-treatment, with some additional weak expression
in acinar cells (arrows). At E16.5, however, the transgene was expressed weakly in the cord region and strongly in the acinar cells, with or without zinc treatment. At
E18.5, essentially all of the transgene expression was in the acini, and the level of expression did not appear different between zinc-treated or -untreated groups. Scale
bar 60 μm.
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different mix-and-match groups were made (Fig. 8A). The
recombination of wild-type epithelia and wild-type mesench-
yme was considered as a control (Figs. 8Ac, g, k). The other
recombinations were between wild-type epithelium and
transgenic mesenchyme, transgenic epithelium and wild-
type mesenchyme or transgenic epithelium and transgenic
mesenchyme. 100 μM ZnCl2 was supplemented in the media
of all of the cultures to enhance transgene expression.
Immunohistochemical staining (Fig. 8A) and quantitative
analysis (Fig. 8B) showed that wild-type epithelium
recombined with wild-type mesenchyme had the lowest
amount of insulin-positive cells and the greatest amount of
amylase staining. When transgenic (TGF-βRII blocked)
epithelium was recombined with either wild-type or transgenic
mesenchyme, there was an augmentation in the number of
insulin-positive cells. However, the greatest augmentation of
insulin-positive area was seen when transgenic mesenchyme was
recombined with wild-type epithelium (Figs. 8Aa, e, i and B).
PDX-1 staining suggested that most or all of the insulin-positive
endocrine cells were mature β-cells (Figs. 8Ai, j, k, l). These
results indicate that TGF-β receptor II signaling is important in
both epithelium and mesenchyme, and perhaps more so in the
mesenchyme.In vitro TGF-β pan-neutralizing antibody experiment
In order to inhibit TGF-β isoform signaling through a
different mechanism, and at a different level (ligand rather than
receptor), we used TGF-β ligand pan-neutralizing antibodies to
determine whether endocrine upregulation would be reproduci-
ble in normal embryos through in vitro manipulation. Treatment
with 80 μg/ml neutralizing antibody led to a more than two-fold
increase in insulin-positive cells (Figs. 9Ag and B). Co-
expression of PDX-1 in these insulin-positive cells again
suggested that the cells were mature β-cells (Fig. 9Ah). Rabbit
non-immune serum control at a similar concentration had no
effect (Figs. 9Aa–d).
Discussion
TGF-β isoform signaling appears to have a complex
influence on pancreatic lineage selection and differentiation.
When TGF-β1 was expressed under the rat insulin promoter in
adult mice, suppression of acinar growth was seen (Lee et al.,
1995). Similarly, Sanvito et al. (1994) showed that exogenous
TGF-β1 caused apoptosis of developing pancreatic acinar cells
with what appeared to be a relative increase in endocrine
elements. Based on this last study, the possibility was raised that
Fig. 7. Quantitative analysis: quantification of mRNA for endogenous TGF-β receptors (A–C), transgenic receptor (D) and TGF-β ligands (E–G) were performed at
various gestational time points by semi-quantitative RT-PCR. The endogenous TGF-β RII mRNA level gradually increased over gestation (A). TGF-β RI/ALK5
mRNA showed its highest level of expression at E16.5 and then a sharp decline at E18.5 (B). The drop in ALK5 mRNA levels at E18.5 suggests that other ALKs,
particularly ALK1, may instead dimerize with TGF-βRII to mediate actions such as blood vessel development. The mRNA level of ALK1 showed a sudden rise late in
gestation, consistent with a possible role in blood vessel development and growth (C). Quantification of the transgenic receptor showed significant upregulation of
expression in zinc-treated pancreas at E11.5, E12.5 and E14.5 compared to untreated embryos (D and inset). However, baseline expression of the transgene at E16.5
and E18.5 becomes very high even in the absence of zinc, probably due to zinc-independent expression of the transgene in acinar tissue. Addition of zinc at these later
ages did not affect the expression level of the transgene. The relative level of TGF-β isoform ligand mRNA were similar between wild-type and transgenic mice
through E16.5. However, the level of expression then differed selectively at E18.5. The level of TGF-β1 and TGF-β3 mRNA significantly increased in transgenic
pancreas treated with zinc, whereas TGF-β2 mRNA was decreased. *P value <0.05.
517S.S. Tulachan et al. / Developmental Biology 305 (2007) 508–521TGF-β isoforms may have a pro-endocrine role in the
developing pancreas. Data presented in that study were based
on explant culture of E11.5/12.5 mouse pancreas treated with
exogenous TGF-β1. Moreover, an initial five-day culture with
TGF-β1 had no effect on endocrine/exocrine differentiation.
When the culture was maintained for more than 10 days in
collagen I gel, the pancreas showed a sharp decrease in acinar
cells, with a relative sparing of endocrine cells. In contrast, a
study performed by Miralles et al. (1998a) in E12.5 rat pancreas
rudiment cultured for 7 days showed no significant difference in
the total number of endocrine/exocrine cells when treated with
exogenous TGF-β1 at the same concentration as Sanvito et al.
These results suggest that the decrease in acinar and increase in
endocrine differentiation perceived by Sanvito et al. may have
been due to the prolonged 10-day culture period. This longer
period may have allowed autolysis of acinar cells due to the
release of acinar digestive enzymes.
Early embryonic lethal phenotypes of TGF-β receptor type II
null mutants, as well as of double and triple null mutants for the
TGF-β isoforms, make interpretation of the role of TGF-β
isoform signaling at the genetic level in the pancreas difficult to
determine. A dominant-negative form of TGF-β type II receptor
was described in 1997 (Bottinger et al., 1997). While the
embryonic phenotype was not investigated, the adult phenotype
was specifically pancreatic, with acinar atypia and ductal
hyperplasia, with occasional acinar tumor formation. Here we
found that inhibition of TGF-β receptor type II signaling led to
an enhanced number of periductal endocrine cells, with vascularectasia and stasis, during mid-to-late gestation. In order to
understand the mechanism of these effects, we needed to study
the distribution and level of expression of both the transgenic
dominant-negative receptor (identified through human-specific
moieties in the receptor) and the endogenous receptor. Knowl-
edge of the distribution and the levels of expression is necessary
for understanding the mechanisms of the dominant-negative
effect since dominant-negative inhibition requires higher
expression of the transgene specifically in cells that also
express the endogenous TGF-β receptor type II. In addition, we
could enhance transgene expression using zinc added either to
the mother’s drinking water or to the culture medium for in vitro
grown tissues.
The increased number of insulin-positive cells in embryonic
pancreata with blocked TGF-β isoform signaling appears to be
partially mediated through both epithelial and mesenchymal
TGF-β receptor type II signaling. The endocrine enhancement
was shown in vivo in the transgenic animals, as well as in vitro
using hybrid transgenic/wild-type pancreatic epithelial/
mesenchymal constructs, or wild-type tissues treated with
pan-neutralizing TGF-β isoform antibodies. Importantly, the
endogenous receptor was seen to be expressed both in the
epithelium and the mesenchyme at critical early times when
lineage selection is occurring. Qualitatively, the endogenous
receptor expression levels appeared to be lower in the
mesenchyme, which may therefore be more easily overridden
by the dominant-negative receptor (the transgenic dominant-
negative receptor was also expressed in both epithelium and
Fig. 8. In vitro mix-and-match experiment: four different mix-and-match in vitro recombinations between transgenic (DNTβRII) and wild-type (CD1) E11.5 pancreatic
epithelium (e) and mesenchyme (m) were made. The recombination of wild-type mesenchyme and wild-type epithelium was considered as a control (c, g, k). 100 μM
ZnCl2 was supplemented in the media of all the cultures to enhance transgene expression. Immunohistochemical staining (A) and quantitative analysis (B) showed that
control cultures had the lowest amount of insulin-positive cells and the greatest amount of amylase staining. When transgenic epithelium was recombined with either
wild-type or transgenic mesenchyme, there was an augmentation of insulin-positive cells. However, the greatest augmentation of insulin-positive area was seen with
recombination of transgenicmesenchymewith wild-type epithelium (a, e, i and B). PDX-1 staining suggested that most or all of the insulin-positive endocrine cells were
mature β-cells (i–l). Scale bar (a–d) 60 μm and (e–l and a–d inset) 120 μm.
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which could explain the greater endocrine enhancement with
isolated transgenic mesenchyme combined with wild-type
epithelium in the mix-and-match experiments.
TGF-β isoform signaling has been found to typically
promote differentiation and growth arrest in epithelia; however,
in stroma or mesenchyme it typically has the opposite effect,promoting growth. This differential action between epithelium
and stroma (mesenchyme) may also be occurring in the early
(E11.5–E12.5) embryonic pancreas. Thus, contrary to hypoth-
eses presented from earlier work in the field, TGF-β signaling
to the epithelium may actually directly suppress endocrine
proliferation and enhance endocrine differentiation, whereas
TGF-β signaling to the mesenchyme may promote mesenchy-
Fig. 9. In vitro neutralizing antibody experiment: in order to inhibit TGF-β isoform signaling at the ligand level, TGF-β pan-neutralizing antibodies were used.
Treatment with 80 μg/ml neutralizing antibody (e–h) showed a significant increase in insulin-positive cells (P value < 0.05) (B). PDX-1 (red) staining of these insulin-
positive cells suggested that the cells were mature β-cells (d and h). Rabbit non-immune serum control at a similar concentration had no effect (a–d). *P value <0.05
and scale bar (b–d and f–h) 120 μm.
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mesenchyme is a pro-exocrine agent during the early critical
times of pancreatic lineage selection, enhanced proliferation of
mesenchyme (induced by TGF-β signaling) may thus favor
exocrine differentiation over endocrine differentiation. In
addition, since vasculogenesis arises from the mesenchyme,
and blood vessel proximity to pancreatic endoderm has been
shown to promote endocrine differentiation (Lammert et al.,
2001), enhanced vasculogenesis due to ALK-1 signaling
inhibition could be playing a role in enhanced endocrine
differentiation as well.
The pro-endocrine effect produced by TGF-β signaling
inhibition was most prominent at E16.5. This gestational time
corresponds to the height of the secondary wave of endocrine
differentiation in the developing mouse pancreas. TGF-β
isoform signaling, which typically acts as a suppressor of
epithelial proliferation, may act as a negative regulator of the
secondary wave of insulin cell proliferation and differentia-tion from ducts. Our in vivo study suggested that the
inhibition of TGF-β isoform signaling in these tissues leads
to an increase in pro-endocrine as well as proliferating
endocrine cells. The rapid cessation of proliferation between
E16.5 and E18.5 could be due to an inappropriate commit-
ment of cells to the endocrine lineage, perhaps with premature
terminal differentiation. Alternatively, the cessation could be
due to loss of TGF-β signaling inhibition due to changes in
the expression of the endogenous and transgenic receptor that
occurs during that gestational time window. Our ontogeny
analysis suggested that the endogenous type II TGF-β
receptor is expressed in the epithelium early in gestation,
which at that time may be dimerizing with the ALK5 type I
receptor to regulate lineage selection. Later in gestation, both
the TGF-β type II receptor and the ALK5 type I receptor
appeared to be most strongly expressed in ducts, possibly
acting as a control mechanism for the generation of endocrine
cells from ducts.
520 S.S. Tulachan et al. / Developmental Biology 305 (2007) 508–521Bottinger et al. (1997) reported acinar atypia with some
acinar cell tumors in adult DNTβRII transgenic mice, but
with no obvious endocrine phenotype. We found normal-
ization of the endocrine phenotype in late gestation. This
normalization may be explained by changes in the expression
pattern of the dominant-negative receptor, which becomes
exclusively expressed in acinar cells. Likewise, changes in the
level of TGF-β isoform ligands may override the dominant-
negative effect in endocrine cells, leading to conditions
favoring early apoptotic death of endocrine cells (Supple-
mentary Fig. 3).
Our findings of increased CD-31 staining and vascular
ectasia in the late gestation transgenic embryonic pancreas
may be due to blocked signaling through the TGF-β type II
receptor dimerized with the ALK1 type I receptor. ALK1 has
been shown to compete with ALK5 for TGF-β receptor type
II binding, particularly in endothelial progenitor cells (Gou-
mans et al., 2002, 2003), and hereditary hemorrhagic
telangiectasia, often in the pancreas, has been associated
with ALK1 mutations in animals and humans (Azuma, 2000;
Chuang et al., 1977; Halpern et al., 1968; Torsney et al.,
2003). In addition, we found that both TGF-β receptor type II
and ALK1 type I receptor were strongly expressed in
developing blood vessels during late phases of pancreatic
development.
In conclusion, our results expand on the early reports of
the role of TGF-β isoform signaling in pancreatic develop-
ment, perhaps now with a better understanding of specific
pathways involved. TGF-β isoforms may have variable
functions throughout pancreatic development. During early–
mid gestation, TGF-β isoforms appear to signal through a
heterodimeric complex of type II and ALK5 receptors to
control endocrine proliferation and differentiation. TGF-β
isoform signaling between epithelium and mesenchyme may
play an important role in the endocrine versus exocrine
lineage determination and the first wave of endocrine
development. However, evidence in the literature suggests
that this first wave may be vestigial and the secondary
transition is more significant with respect to final beta cell
mass. TGF-β isoform signaling appears to be critically
important for suppressing the proliferation and differentiation
of pro-endocrine cells in the ductal and periductal region of
the mid-gestation pancreas.
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